Combination of p53 and Ki67 as a Promising Predictor of Postoperative Recurrence of Meningioma
- PMID: 33419814
- DOI: 10.21873/anticanres.14766
Combination of p53 and Ki67 as a Promising Predictor of Postoperative Recurrence of Meningioma
Abstract
Background: Meningioma is a common intracranial tumor originating from arachnoid cap cells. Meningiomas are generally benign tumors curable by one-time resection. However, some meningiomas regrow and invade into the dura mater, and thus frequently require additional treatment. A useful marker to predict the regrowth of meningioma is desired. This study aimed to clarify the significance of p53 and Ki67 for postoperative recurrence of meningioma.
Materials and methods: The expression of p53 and Ki67 in 215 intracranial or intraspinal meningiomas was investigated by immunohistochemistry.
Results: Of the 215 meningiomas, 35 cases (16.3%) were p53-positive and 49 cases (22.8%) were Ki67-positive. Multivariate analysis revealed Ki67 and p53 status as being significantly correlated with recurrence. Positivity for either Ki67- or p53 was significantly associated with poor recurrence-free survival.
Conclusion: Combined p53 and Ki67 status might represent a useful independent predictive marker for recurrence of meningioma.
Keywords: Ki67; Meningioma; immunostaining; p53; recurrence.
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Similar articles
-
Tissue thioredoxin-interacting protein expression predicted recurrence in patients with meningiomas.Int J Clin Oncol. 2017 Aug;22(4):660-666. doi: 10.1007/s10147-017-1103-4. Epub 2017 Feb 27. Int J Clin Oncol. 2017. PMID: 28243945
-
Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.APMIS. 2009 Sep;117(9):651-9. doi: 10.1111/j.1600-0463.2009.02516.x. APMIS. 2009. PMID: 19703125
-
Clinicopathological Impact of FOXM1 and MMP-9 Immunohistochemical Expression in Different Grades of Intracranial Meningioma.Appl Immunohistochem Mol Morphol. 2024 Jul 1;32(6):292-304. doi: 10.1097/PAI.0000000000001205. Epub 2024 Jun 12. Appl Immunohistochem Mol Morphol. 2024. PMID: 38863278
-
Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.PLoS One. 2024 May 17;19(5):e0303337. doi: 10.1371/journal.pone.0303337. eCollection 2024. PLoS One. 2024. PMID: 38758750 Free PMC article.
-
The prognostic role of Ki-67/MIB-1 in meningioma: A systematic review with meta-analysis.Medicine (Baltimore). 2020 Feb;99(9):e18644. doi: 10.1097/MD.0000000000018644. Medicine (Baltimore). 2020. PMID: 32118704 Free PMC article.
Cited by
-
Caspase 3 Expression Profiles in Meningioma Subtypes Based on Tissue Microarray Analysis.Cancer Diagn Progn. 2024 Sep 1;4(5):586-591. doi: 10.21873/cdp.10367. eCollection 2024 Sep-Oct. Cancer Diagn Progn. 2024. PMID: 39238614 Free PMC article.
-
P53 Suppressor Gene Tissue Microarray-based Protein Expression Analysis in Meningiomas.In Vivo. 2022 Sep-Oct;36(5):2205-2210. doi: 10.21873/invivo.12946. In Vivo. 2022. PMID: 36099147 Free PMC article.
-
A High MCM6 Proliferative Index in Atypical Meningioma Is Associated with Shorter Progression Free and Overall Survivals.Cancers (Basel). 2023 Jan 16;15(2):535. doi: 10.3390/cancers15020535. Cancers (Basel). 2023. PMID: 36672484 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous